https://www.selleckchem.com/pr....oducts/pemigatinib-i
Some patients may prefer to taper at 10% or less of their most recent dose each month. This process might allow underlying adaptations time to resolve, possibly reducing the risk of relapse on discontinuation. Final doses before complete cessation may need to be as small as 1/40th a therapeutic dose to prevent a large decrease in D2 blockade when stopped. This proposal should be tested in randomized controlled trials.In plants with Crassulacean acid metabolism (CAM), it has been proposed that the requirement for nocturnal
Like
Comment
Share
